[HTML][HTML] Why 90% of clinical drug development fails and how to improve it?

D Sun, W Gao, H Hu, S Zhou - Acta Pharmaceutica Sinica B, 2022 - Elsevier
Ninety percent of clinical drug development fails despite implementation of many successful
strategies, which raised the question whether certain aspects in target validation and drug …

Delivering precision oncology to patients with cancer

J Mateo, L Steuten, P Aftimos, F André, M Davies… - Nature medicine, 2022 - nature.com
With the increasing use of genomic profiling for diagnosis and therapy guidance in many
tumor types, precision oncology is rapidly reshaping cancer care. However, the current …

[HTML][HTML] Conserved pan-cancer microenvironment subtypes predict response to immunotherapy

A Bagaev, N Kotlov, K Nomie, V Svekolkin, A Gafurov… - Cancer cell, 2021 - cell.com
The clinical use of molecular targeted therapy is rapidly evolving but has primarily focused
on genomic alterations. Transcriptomic analysis offers an opportunity to dissect the …

Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors

CA Milbury, J Creeden, WK Yip, DL Smith, V Pattani… - PLoS …, 2022 - journals.plos.org
FoundationOne® CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-
approved companion diagnostic test to identify patients who may benefit from treatment in …

Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme

A Sosinsky, J Ambrose, W Cross, C Turnbull… - Nature Medicine, 2024 - nature.com
Abstract The Cancer Programme of the 100,000 Genomes Project was an initiative to
provide whole-genome sequencing (WGS) for patients with cancer, evaluating opportunities …

From target discovery to clinical drug development with human genetics

K Trajanoska, C Bhérer, D Taliun, S Zhou, JB Richards… - Nature, 2023 - nature.com
The substantial investments in human genetics and genomics made over the past three
decades were anticipated to result in many innovative therapies. Here we investigate the …

Multimodal data fusion for cancer biomarker discovery with deep learning

S Steyaert, M Pizurica, D Nagaraj… - Nature machine …, 2023 - nature.com
Technological advances have made it possible to study a patient from multiple angles with
high-dimensional, high-throughput multiscale biomedical data. In oncology, massive …

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment

A Friedlaender, V Subbiah, A Russo… - Nature reviews Clinical …, 2022 - nature.com
Protein tyrosine kinases of the human epidermal growth factor receptor family, including
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …

Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells

Y Sun, N Berleth, W Wu, D Schlütermann… - Cell death & …, 2021 - nature.com
Ferroptosis is a form of regulated cell death that emerges to be relevant for therapy-resistant
and dedifferentiating cancers. Although several lines of evidence suggest that ferroptosis is …

Therapy-induced senescence: opportunities to improve anticancer therapy

PG Prasanna, DE Citrin, J Hildesheim… - JNCI: Journal of the …, 2021 - academic.oup.com
Cellular senescence is an essential tumor suppressive mechanism that prevents the
propagation of oncogenically activated, genetically unstable, and/or damaged cells …